Seeking Alpha

Endologix (ELGX) reports preliminary unaudited sales for Q2 of ~$34M (+33% Y/Y) and raises FY13...

Endologix (ELGX) reports preliminary unaudited sales for Q2 of ~$34M (+33% Y/Y) and raises FY13 revenue guidance to $128-134M. The company now projects a wider net loss than previously expected however and also says it is temporarily suspending enrollment in its Ventana U.S. IDE clinical trial. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs